Endometrial Cancer Clinical Trial
Official title:
Effect of a Uterine Manipulator on the Incidence of Lymphovascular Propagation (LVSI) in Treatment of Endometrial Cancer
NCT number | NCT05261165 |
Other study ID # | 29/2021 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 1, 2015 |
Est. completion date | October 1, 2021 |
Verified date | February 2022 |
Source | F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
We retrospectively analyzed data and compared the impact of intrauterine manipulators on incidence of LVSI in endometrial cancer patients treated at our department.
Status | Completed |
Enrollment | 170 |
Est. completion date | October 1, 2021 |
Est. primary completion date | January 1, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - endometrioid endometrial cancer, - planned primary surgical treatment - hysterectomy, - medical condition enabling anesthesia and surgery, - pre-surgical clinically-determined affecting of the uterine according to MRI or ultrasound - cT1a or cT1b Exclusion Criteria: - non-endometrioid type of tumor in definitive histology, - stage 2 of a disease and higher, - previous chemo or radiotherapy, - inability to adequately complete the surgery, - uterine perforation during surgery |
Country | Name | City | State |
---|---|---|---|
Slovakia | F.D. Roosevelt Teaching Hospital with Policlinic | Banská Bystrica |
Lead Sponsor | Collaborator |
---|---|
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica |
Slovakia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | LVSI and grading of tumor | Connection between grading of tumor and incidence of LVSI | oct. 2015 - jan. 2021 | |
Other | LVSI and myometrial invasion | Connection between myometrial invasion of tumor and incidence of LVSI | oct. 2015 - jan. 2021 | |
Other | LVSI and primary histology procedure | Method of obtaining primary histology, hysteroscopy or curettage in connection to incidence of LVSI. | oct. 2015 - jan. 2021 | |
Primary | LVSI and intrauterine manipulator | Finding of the difference in the incidence of LVSI in female patients with and without an intrauterine manipulator | oct. 2015 - jan. 2021 | |
Secondary | LVSI and type of intrauterine manipulator | The effect of a type of an intrauterine manipulator on the incidence of LVSI | oct. 2015 - jan. 2021 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02549989 -
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
|
Phase 2 |